Literature DB >> 18417036

Treatment of hepatitis C genotype 2/3.

Bruce R Bacon.   

Abstract

Entities:  

Year:  2008        PMID： 18417036     DOI： 10.1007/s11894-008-0002-2

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN： 1522-8037


× No keyword cloud information.
  6 in total

1.  Diagnosis, management, and treatment of hepatitis C.

Authors:  Doris B Strader; Teresa Wright; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

2.  Shortened therapy for hepatitis C virus genotype 2 or 3--is less more?

Authors:  T Jake Liang
Journal:  N Engl J Med       Date:  2007-07-12       Impact factor: 91.245

3.  Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

Authors:  Michael von Wagner; Miriam Huber; Thomas Berg; Holger Hinrichsen; Jens Rasenack; Tobias Heintges; Alexandra Bergk; Christine Bernsmeier; Dieter Häussinger; Eva Herrmann; Stefan Zeuzem
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

4.  A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.

Authors:  Ming-Lung Yu; Chia-Yen Dai; Jee-Fu Huang; Nai-Jen Hou; Li-Po Lee; Ming-Yen Hsieh; Chang-Fu Chiu; Zu-Yau Lin; Shinn-Cherng Chen; Ming-Yuh Hsieh; Liang-Yen Wang; Wen-Yu Chang; Wan-Long Chuang
Journal:  Gut       Date:  2006-09-06       Impact factor: 23.059

5.  Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

Authors:  Alessandra Mangia; Rosanna Santoro; Nicola Minerva; Giovanni L Ricci; Vito Carretta; Marcello Persico; Francesco Vinelli; Gaetano Scotto; Donato Bacca; Mauro Annese; Mario Romano; Franco Zechini; Fernando Sogari; Fulvio Spirito; Angelo Andriulli
Journal:  N Engl J Med       Date:  2005-06-23       Impact factor: 91.245

6.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.